Jemincare Group, a China-based pharmaceutical company, has started the phase one clinical trial of anti-SARS-CoV-2 neutralising antibody (JMB2002), it was reported on Wednesday.

The company conducted preclinical studies of the product including pharmacology and toxicity systemically. It was found in early studies that the product effectively neutralised live virus infection of Vero E6 cells and indicated potent binding and blocking activities to the spike glycoproteins of mutant viruses.

Jemincare said that while most of the SARS-CoV-2 neutralising antibodies in clinical trial are produced from cell pool, the product for clinical trial of JMB2002 is produced from high yield stable cell line, that ensure the consistency and stability of clinical samples. The product is derived from the naive human B cell antibody library of healthy donors. With the powerful phage-to-yeast platform, researchers quickly pinpoint the ideal candidates from over 10 billion antibody molecules in 19 days.